IPO Year:
Exchange: NYSE
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/28/2024 | $130.00 | Equal Weight | Wells Fargo |
7/8/2024 | $125.00 | Outperform | Leerink Partners |
6/3/2024 | $115.00 | Hold | Jefferies |
1/16/2024 | $105.00 → $125.00 | Buy → Neutral | UBS |
1/4/2024 | $88.00 → $125.00 | In-line → Outperform | Evercore ISI |
12/19/2023 | $95.00 | Equal Weight | Wells Fargo |
12/13/2023 | Peer Perform | Wolfe Research | |
9/28/2023 | $133.00 | Outperform | Bernstein |
7/19/2023 | $145.00 | Outperform | Raymond James |
5/23/2023 | $150.00 | Buy | Goldman |
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
11-K - REVVITY, INC. (0000031791) (Filer)
SD - REVVITY, INC. (0000031791) (Filer)
10-Q - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
8-K - REVVITY, INC. (0000031791) (Filer)
ARS - REVVITY, INC. (0000031791) (Filer)
DEFA14A - REVVITY, INC. (0000031791) (Filer)
DEF 14A - REVVITY, INC. (0000031791) (Filer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
4 - REVVITY, INC. (0000031791) (Issuer)
Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $130.00
Leerink Partners initiated coverage of Revvity with a rating of Outperform and set a new price target of $125.00
Jefferies resumed coverage of Revvity with a rating of Hold and set a new price target of $115.00
UBS downgraded Revvity from Buy to Neutral and set a new price target of $125.00 from $105.00 previously
Evercore ISI upgraded Revvity from In-line to Outperform and set a new price target of $125.00 from $88.00 previously
Wells Fargo initiated coverage of Revvity with a rating of Equal Weight and set a new price target of $95.00
Wolfe Research initiated coverage of Revvity with a rating of Peer Perform
Bernstein initiated coverage of Revvity with a rating of Outperform and set a new price target of $133.00
Raymond James initiated coverage of Revvity with a rating of Outperform and set a new price target of $145.00
Goldman resumed coverage of Revvity with a rating of Buy and set a new price target of $150.00
Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences in September 2024: 2024 Wells Fargo Healthcare Conference – Boston, MA Wednesday, September 4, 2024 8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2024 Baird Global Healthcare Conference – New York City, NY Tuesday, September 10, 2024 12:15 p.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk Attendees will receive an update on the Company and its strategic priorities. Live audio webcasts will be available on the Events section of the Company's website. Replays of the presentations will be posted on the Revvity Investor Relatio
Revenue of $692 million; (2)% reported growth; (1)% organic growth GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 Raises full year 2024 adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing opera
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo
Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflowVIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE:RVTY) under which Revvity will market and co
Revvity, Inc. (NYSE:RVTY) will present at the 45th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website at www.revvity.com. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solution
Revenue of $650 million; (4)% reported growth; (3)% organic growth First quarter GAAP EPS of $0.21; Adjusted EPS from continuing operations of $0.98 Reaffirms full year 2024 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as compared to $4.50 in the same period a year ago. GAAP revenue for the quarter was $650 million, as compared to $675 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $44 million, as compared to $76 million for the same period a year ago. GAAP operating
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, det
Revvity, Inc. (NYSE:RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website at www.revvity.com. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and will be available for at least 30 days. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutio
New and improved workflow now available that pairs Revvity's T-SPOT™.TB test with the Auto-Pure 2400 liquid handling platform Substantially lowers hands-on time, allowing for increased lab productivity Revvity, Inc. (NYSE:RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the T-SPOT.TB test is combined with the efficiency of the Auto-Pure 2400 system, labs, clinicians and ultimately patients, benefit from the resultant powerful solution. "The ability to use the Auto-Pure 2400 platform with our T-SPO
Revenue of $692 million; (2)% reported growth; (1)% organic growth GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 Raises full year 2024 adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a year ago. GAAP revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $86 million, as compared to $78 million for the same period a year ago. GAAP operating profit margin from continuing opera
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
Revvity, Inc. (NYSE:RVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflo
Revenue of $650 million; (4)% reported growth; (3)% organic growth First quarter GAAP EPS of $0.21; Adjusted EPS from continuing operations of $0.98 Reaffirms full year 2024 organic growth and adjusted EPS guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as compared to $4.50 in the same period a year ago. GAAP revenue for the quarter was $650 million, as compared to $675 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $44 million, as compared to $76 million for the same period a year ago. GAAP operating
The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, det
Revvity, Inc. (NYSE:RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise, and services t
Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth Fourth quarter GAAP EPS of $0.64; Adjusted EPS from continuing operations of $1.25 Initiates full year 2024 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The Company reported GAAP earnings per share of $0.64, as compared to $1.01 in the same period a year ago. GAAP revenue for the quarter was $696 million, as compared to $741 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $77 million, as compared to $1
The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 10, 2024 to all shareholders of record at the close of business on April 19, 2024. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin
Revvity, Inc. (NYSE:RVTY) today announced that it will release its fourth quarter and full year 2023 financial results prior to market open on Thursday, February 1, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available via this registration form or on the Investors section of the Company's website. Update on Financial Performance The Company is providing the following preliminary financial results for the fourth quarter 2023: Revenue for the fourth qu
Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing operations of $1.18 Updates full year 2023 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the third quarter ended October 1, 2023. The Company reported GAAP earnings per share of $0.08, as compared to $0.67 in the same period a year ago. GAAP revenue for the quarter was $671 million, as compared to $712 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $69 million, as compared to $111 million for the same period a year ago. GAAP operating profit margin f
Leerink Partners initiates coverage on Revvity (NYSE:RVTY) with a Outperform rating and announces Price Target of $125.
Barclays analyst Luke Sergott maintains Revvity (NYSE:RVTY) with a Equal-Weight and lowers the price target from $116 to $115.
Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $126 to $127.
During the last three months, 4 analysts shared their evaluations of Revvity (NYSE:RVTY), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 1 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $123.25, along with a high estimate of $130.00 and a low estimate of $110.00. Witnessing a positive shift,
TD Cowen analyst Dan Brennan maintains Revvity (NYSE:RVTY) with a Buy and raises the price target from $123 to $130.
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc. (NASDAQ:AMZN) on Tuesday and Apple Inc. (NASDAQ:AAPL) on Thursday, a pivotal Federal Reserve Open Market Committee meeting on Wednesday, and the April’s jobs report on Friday. The S&P 500 rose 0.2% by midday trading in New York, following a 1% surge last Friday. Both the tech-heavy Nasdaq 100 and blue-chip stocks in the Dow Jones made similar gains. Small caps, as tracked by iShares Russell 2000 ETF (NYSE:IWM), outperformed large-cap stocks, rising as much as 0.9%. Tesla Inc. (NASDAQ:TSLA) g
Revvity (NYSE:RVTY) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.93 by 5.38 percent. This is a 2.97 percent decrease over earnings of $1.01 per share from the same period last year. The company reported quarterly sales of $649.920 million which beat the analyst consensus estimate of $646.843 million by 0.48 percent. This is a 3.70 percent decrease over sales of $674.865 million the same period last year.